Literature DB >> 29753269

Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Tara E Tracy1, Li Gan2.   

Abstract

The accumulation of pathological tau in the brain is associated with neuronal deterioration and cognitive impairments in tauopathies including Alzheimer's disease. Tau, while primarily localized in the axons of healthy neurons, accumulates in the soma and dendrites of neurons under pathogenic conditions. Tau is found in both presynaptic and postsynaptic compartments of neurons in Alzheimer's disease. New research supports that soluble forms of tau trigger pathophysiology in the brain by altering properties of synaptic and neuronal function at the early stages of disease progression, before neurons die. Here we review the current understanding of how tau-mediated synaptic and neuronal dysfunction contributes to cognitive decline. Delineating the mechanisms by which pathogenic tau alters synapses, dendrites and axons will help lay the foundation for new strategies that can restore neuronal function in tauopathy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29753269      PMCID: PMC6130905          DOI: 10.1016/j.conb.2018.04.027

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  49 in total

Review 1.  Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.

Authors:  Stefania Forner; David Baglietto-Vargas; Alessandra C Martini; Laura Trujillo-Estrada; Frank M LaFerla
Journal:  Trends Neurosci       Date:  2017-05-08       Impact factor: 13.837

2.  Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.

Authors:  Diana L Castillo-Carranza; Julia E Gerson; Urmi Sengupta; Marcos J Guerrero-Muñoz; Cristian A Lasagna-Reeves; Rakez Kayed
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

4.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Authors:  Cristian A Lasagna-Reeves; Diana L Castillo-Carranza; Urmi Sengupta; Jose Sarmiento; Juan Troncoso; George R Jackson; Rakez Kayed
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

5.  Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.

Authors:  Sang-Won Min; Xu Chen; Tara E Tracy; Yaqiao Li; Yungui Zhou; Chao Wang; Kotaro Shirakawa; S Sakura Minami; Erwin Defensor; Sue Ann Mok; Peter Dongmin Sohn; Birgit Schilling; Xin Cong; Lisa Ellerby; Bradford W Gibson; Jeffrey Johnson; Nevan Krogan; Mehrdad Shamloo; Jason Gestwicki; Eliezer Masliah; Eric Verdin; Li Gan
Journal:  Nat Med       Date:  2015-09-21       Impact factor: 53.440

6.  Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment.

Authors:  Robert John Hatch; Yan Wei; Di Xia; Jürgen Götz
Journal:  Acta Neuropathol       Date:  2017-01-16       Impact factor: 17.088

Review 7.  Propagation of Tau Aggregates and Neurodegeneration.

Authors:  Michel Goedert; David S Eisenberg; R Anthony Crowther
Journal:  Annu Rev Neurosci       Date:  2017-07-25       Impact factor: 12.449

8.  Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells.

Authors:  Marija Usenovic; Shahriar Niroomand; Robert E Drolet; Lihang Yao; Renee C Gaspar; Nathan G Hatcher; Joel Schachter; John J Renger; Sophie Parmentier-Batteur
Journal:  J Neurosci       Date:  2015-10-21       Impact factor: 6.167

9.  Memory retrieval by activating engram cells in mouse models of early Alzheimer's disease.

Authors:  Dheeraj S Roy; Autumn Arons; Teryn I Mitchell; Michele Pignatelli; Tomás J Ryan; Susumu Tonegawa
Journal:  Nature       Date:  2016-03-16       Impact factor: 49.962

10.  TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.

Authors:  Cheryl E G Leyns; Jason D Ulrich; Mary B Finn; Floy R Stewart; Lauren J Koscal; Javier Remolina Serrano; Grace O Robinson; Elise Anderson; Marco Colonna; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

View more
  35 in total

1.  Phosphorylation in two discrete tau domains regulates a stepwise process leading to postsynaptic dysfunction.

Authors:  Peter J Teravskis; Breeta R Oxnard; Eric C Miller; Lisa Kemper; Karen H Ashe; Dezhi Liao
Journal:  J Physiol       Date:  2019-07-07       Impact factor: 5.182

Review 2.  Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies.

Authors:  Che-Wei Chang; Eric Shao; Lennart Mucke
Journal:  Science       Date:  2021-02-26       Impact factor: 47.728

3.  Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.

Authors:  Emily J Koller; Elsa Gonzalez De La Cruz; Timothy Machula; Kristen R Ibanez; Wen-Lang Lin; Tosha Williams; Cara J Riffe; Daniel Ryu; Kevin H Strang; Xuefei Liu; Christopher Janus; Todd E Golde; Dennis Dickson; Benoit I Giasson; Paramita Chakrabarty
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

4.  PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.

Authors:  Hiroyuki Inuzuka; Jing Liu; Wenyi Wei; Abdol-Hossein Rezaeian
Journal:  Acta Mater Med       Date:  2022-01-21

Review 5.  Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease.

Authors:  Ricardo Apátiga-Pérez; Luis O Soto-Rojas; B Berenice Campa-Córdoba; Nabil Itzi Luna-Viramontes; Elvis Cuevas; Ignacio Villanueva-Fierro; Miguel Angel Ontiveros-Torres; Marely Bravo-Muñoz; Paola Flores-Rodríguez; Linda Garcés-Ramirez; Fidel de la Cruz; José Francisco Montiel-Sosa; Mar Pacheco-Herrero; José Luna-Muñoz
Journal:  Metab Brain Dis       Date:  2021-08-18       Impact factor: 3.584

Review 6.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

Review 7.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

8.  The Tetramethylpyrazine Analogue T-006 Alleviates Cognitive Deficits by Inhibition of Tau Expression and Phosphorylation in Transgenic Mice Modeling Alzheimer's Disease.

Authors:  Guiliang Zhang; Jiahui Wu; Chunhui Huang; Jiehong Cheng; Zhiyang Su; Zeyu Zhu; Xifei Yang; Baojian Guo; Liangmiao Wu; Zaijun Zhang; Gaoxiao Zhang; Haiyun Chen; Yewei Sun; Yuqiang Wang
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

9.  RTP801/REDD1 contributes to neuroinflammation severity and memory impairments in Alzheimer's disease.

Authors:  Albert Giralt; Cristina Malagelada; Leticia Pérez-Sisqués; Anna Sancho-Balsells; Júlia Solana-Balaguer; Genís Campoy-Campos; Marcel Vives-Isern; Ferran Soler-Palazón; Marta Anglada-Huguet; Miguel-Ángel López-Toledano; Eva-Maria Mandelkow; Jordi Alberch
Journal:  Cell Death Dis       Date:  2021-06-15       Impact factor: 8.469

10.  A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies.

Authors:  Jie Zheng; Na Tian; Fei Liu; Yidian Zhang; Jingfen Su; Yang Gao; Mingmin Deng; Linyu Wei; Jingwang Ye; Honglian Li; Jian-Zhi Wang
Journal:  Signal Transduct Target Ther       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.